Natera, Inc. (NASDAQ:NTRA) Shares Purchased by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. boosted its position in shares of Natera, Inc. (NASDAQ:NTRA) by 6.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,951 shares of the medical research company’s stock after acquiring an additional 186 shares during the period. PNC Financial Services Group Inc.’s holdings in Natera were worth $467,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Blue Trust Inc. grew its holdings in Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after acquiring an additional 97 shares in the last quarter. Versant Capital Management Inc grew its holdings in Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after acquiring an additional 166 shares in the last quarter. Principal Securities Inc. grew its holdings in Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after acquiring an additional 59 shares in the last quarter. True Wealth Design LLC acquired a new position in Natera during the 3rd quarter worth approximately $57,000. Finally, Steward Partners Investment Advisory LLC grew its holdings in Natera by 1,328.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company’s stock worth $57,000 after acquiring an additional 332 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insiders Place Their Bets

In other Natera news, insider Solomon Moshkevich sold 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $143.29, for a total value of $859,740.00. Following the sale, the insider now owns 143,768 shares in the company, valued at approximately $20,600,516.72. This trade represents a 4.01 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Steven Leonard Chapman sold 6,702 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $146.03, for a total transaction of $978,693.06. Following the completion of the sale, the chief executive officer now owns 203,354 shares in the company, valued at $29,695,784.62. The trade was a 3.19 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 307,466 shares of company stock valued at $49,047,655 over the last quarter. Insiders own 7.60% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on NTRA. Piper Sandler boosted their price target on shares of Natera from $200.00 to $205.00 and gave the stock an “overweight” rating in a report on Tuesday, March 4th. Guggenheim boosted their price objective on shares of Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, January 17th. JPMorgan Chase & Co. boosted their price objective on shares of Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. StockNews.com upgraded shares of Natera from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, Canaccord Genuity Group restated a “buy” rating and set a $180.00 price objective on shares of Natera in a research report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $178.12.

Natera Stock Up 3.1 %

NTRA stock opened at $150.87 on Thursday. The company has a market capitalization of $20.40 billion, a P/E ratio of -85.72 and a beta of 1.80. The firm has a 50 day simple moving average of $162.25 and a 200-day simple moving average of $149.27. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a twelve month low of $83.13 and a twelve month high of $183.00.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $476.10 million for the quarter, compared to analysts’ expectations of $447.91 million. On average, equities research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.